Ellevest Inc. Makes New $400,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

Ellevest Inc. purchased a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 5,140 shares of the medical device company’s stock, valued at approximately $400,000.

Other hedge funds have also modified their holdings of the company. Nordea Investment Management AB increased its holdings in DexCom by 2.8% in the 4th quarter. Nordea Investment Management AB now owns 80,590 shares of the medical device company’s stock worth $6,271,000 after buying an additional 2,183 shares during the period. Watts Gwilliam & Co. LLC acquired a new stake in shares of DexCom in the fourth quarter worth $3,334,000. Czech National Bank raised its holdings in shares of DexCom by 3.7% during the fourth quarter. Czech National Bank now owns 84,689 shares of the medical device company’s stock worth $6,586,000 after purchasing an additional 3,057 shares during the last quarter. Capital Investment Advisors LLC acquired a new position in DexCom during the fourth quarter valued at $206,000. Finally, CHICAGO TRUST Co NA boosted its holdings in DexCom by 67.9% in the fourth quarter. CHICAGO TRUST Co NA now owns 18,236 shares of the medical device company’s stock valued at $1,418,000 after purchasing an additional 7,373 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 13,000 shares of DexCom stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the transaction, the executive vice president now owns 105,602 shares in the company, valued at $7,432,268.76. The trade was a 10.96 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now directly owns 135,482 shares of the company’s stock, valued at $10,002,636.06. This represents a 4.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,926 shares of company stock valued at $4,734,384 in the last ninety days. 0.32% of the stock is currently owned by corporate insiders.

DexCom Stock Down 0.8 %

Shares of DXCM opened at $84.66 on Friday. The stock has a 50 day moving average price of $71.08 and a 200 day moving average price of $77.17. DexCom, Inc. has a one year low of $57.52 and a one year high of $132.26. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The stock has a market capitalization of $33.20 billion, a price-to-earnings ratio of 59.20, a PEG ratio of 2.30 and a beta of 1.43.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.01). The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. DexCom’s quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the company earned $0.32 earnings per share. Equities research analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

DXCM has been the subject of several analyst reports. Cfra Research raised DexCom to a “hold” rating in a report on Friday, March 21st. Morgan Stanley boosted their price target on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Citigroup raised their price objective on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Robert W. Baird decreased their target price on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research note on Friday, May 2nd. Finally, Mizuho initiated coverage on shares of DexCom in a research report on Thursday, April 10th. They set an “outperform” rating and a $85.00 price target on the stock. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.11.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.